Nanjing IASO Biotherapeutics announced that it has raised funds in a round of funding on January 13, 2023. The transaction included participation from new investors, Shanghai Chuanghehui Investment Management Co., Ltd. and Jointown Pharmaceutical Group Co., Ltd.